Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives
Comparative Clinical Pathology · 21.11.2026 · 35 (1)
DOI: 10.1007/s00580-026-03894-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comparative Clinical Pathology, online erschienen am 21.11.2026. Verfasst von Paari Ellappan und 2 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ellappan, P., Rajendran, S., & Selvamurugan, T. (2026). Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives. Comparative Clinical Pathology, 35(1). https://doi.org/10.1007/s00580-026-03894-9
Vancouver
Ellappan P, Rajendran S, Selvamurugan T. Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives. Comparative Clinical Pathology. 2026;35(1). doi:10.1007/s00580-026-03894-9
BibTeX
@article{Ellappan2026,
author = {Ellappan, Paari and Rajendran, Sivaa and Selvamurugan, Tamilarasi},
title = {Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives},
journal = {Comparative Clinical Pathology},
year = {2026},
volume = {35},
number = {1},
doi = {10.1007/s00580-026-03894-9}
}
EUVIMED